For cancer treatment, local delivery is a promising way to avoid unnecessary exposure of healthy tissue to potent anti-cancer drugs. In lung cancer specifically, local delivery via inhalation using a dry powder inhaler may be particularly advantageous to the patient: it is non-invasive, convenient to administer, and requires no clinic visit.  In this on-demand talk, it will be presented Lonza’s approach to formulation and manufacturing of local lung cancer treatments by dry powder inhaler. Additionally, there are two case studies discussed: bevacizumab (a monoclonal antibody) and 5-azacytidine (a small molecule).
By clicking "Access Content" you agree to our Legal Disclaimer and the Lonza Privacy and Cookies Policy.

Latest content
Latest briefing from the Knowledge Center